Illumina, Inc. (ILMN)
ILMN Q4 Earnings Miss Estimates, Stock Dips in Aftermarket
Illumina's fourth-quarter revenues from the consumables business show robust growth.
Illumina, Inc. (ILMN) Q4 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Conor McNamara - RBC Capital Markets Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies David Westenberg - Piper Sandler Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Patrick Donnelly - Citi Operator Good day, ladies and gentlemen and welcome to the Fourth Quarter 2024 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina (ILMN) Q4 Earnings Miss Estimates
Illumina (ILMN) came out with quarterly earnings of $0.86 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.14 per share a year ago.
Illumina forecasts 2025 revenue largely below estimates
Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling subdued demand for its genetic tests and diagnostic tools, sending shares down nearly 4% in extended trading.
Why Illumina Stock Plummeted Today
Genomic sequencing specialist Illumina (ILMN -5.26%) was something of a victim in the U.S.-China trade spat on Tuesday. The government of the sprawling Asian nation placed the U.S. company on a blacklist, and given the size and power of that economy, investors weren't happy about the news.
Curious about Illumina (ILMN) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
